Long-term influence of combined oral contraceptive use on the clinical course of relapsing-remitting multiple sclerosis

Giulia Gava, Ilaria Bartolomei, Antonietta Costantino, Marta Berra, Stefano Venturoli, Fabrizio Salvi, Maria Cristina Meriggiola

Research output: Contribution to journalArticle

Abstract

Objective To assess the long-term effects of combined oral contraceptives (COCs) on the clinical course of relapsing-remitting multiple sclerosis (RRMS), focusing on disability progression and evolution to secondary-progressive multiple sclerosis (SPMS). Design Retrospective and exploratory study. Setting Academic medical center. Patient(s) A total of 174 women with clinically confirmed MS; of these, 33 had evolved to SPMS at the time of enrollment in the study, whereas 141 still had a relapsing-remitting form of disease. Intervention(s) Women were interviewed to obtain gynecologic and obstetric history. Main Outcome Measure(s) Expanded Disability Status Scale (EDSS); Multiple Sclerosis Severity Score (MSSS); annualized relapse rate; evolution to SPMS. Result(s) Mean ± SD duration of disease was 14.3 ± 9.8 years. Compared with non-users of COCs, COC users had lower EDSS scores and MSSS only in the subset of the population with prior or current immunomodulatory treatment. Nonuse of COCs was a predictor of disease evolution in SPMS, whether treated or not with immunomodulatory drugs. The annualized relapse rate was not influenced by COC use. No differences in EDSS scores and evolution to SPMS depending on COC formulation were detected. Conclusion(s) Our results suggest that COC use is associated with a less severe disease and less severe evolution. Whether different doses or types of progestin may have different effects remains to be defined.

Original languageEnglish
Pages (from-to)116-122
Number of pages7
JournalFertility and Sterility
Volume102
Issue number1
DOIs
Publication statusPublished - 2014

Fingerprint

Contraceptives, Oral, Combined
Relapsing-Remitting Multiple Sclerosis
Chronic Progressive Multiple Sclerosis
Multiple Sclerosis
Recurrence
Progestins
Obstetrics
Retrospective Studies
History
Outcome Assessment (Health Care)

Keywords

  • Disability
  • multiple sclerosis
  • neurologic outcome
  • oral contraceptives
  • sex steroids

ASJC Scopus subject areas

  • Obstetrics and Gynaecology
  • Reproductive Medicine

Cite this

Long-term influence of combined oral contraceptive use on the clinical course of relapsing-remitting multiple sclerosis. / Gava, Giulia; Bartolomei, Ilaria; Costantino, Antonietta; Berra, Marta; Venturoli, Stefano; Salvi, Fabrizio; Meriggiola, Maria Cristina.

In: Fertility and Sterility, Vol. 102, No. 1, 2014, p. 116-122.

Research output: Contribution to journalArticle

Gava, Giulia ; Bartolomei, Ilaria ; Costantino, Antonietta ; Berra, Marta ; Venturoli, Stefano ; Salvi, Fabrizio ; Meriggiola, Maria Cristina. / Long-term influence of combined oral contraceptive use on the clinical course of relapsing-remitting multiple sclerosis. In: Fertility and Sterility. 2014 ; Vol. 102, No. 1. pp. 116-122.
@article{57908959048f4b79b726a7b3c86562f9,
title = "Long-term influence of combined oral contraceptive use on the clinical course of relapsing-remitting multiple sclerosis",
abstract = "Objective To assess the long-term effects of combined oral contraceptives (COCs) on the clinical course of relapsing-remitting multiple sclerosis (RRMS), focusing on disability progression and evolution to secondary-progressive multiple sclerosis (SPMS). Design Retrospective and exploratory study. Setting Academic medical center. Patient(s) A total of 174 women with clinically confirmed MS; of these, 33 had evolved to SPMS at the time of enrollment in the study, whereas 141 still had a relapsing-remitting form of disease. Intervention(s) Women were interviewed to obtain gynecologic and obstetric history. Main Outcome Measure(s) Expanded Disability Status Scale (EDSS); Multiple Sclerosis Severity Score (MSSS); annualized relapse rate; evolution to SPMS. Result(s) Mean ± SD duration of disease was 14.3 ± 9.8 years. Compared with non-users of COCs, COC users had lower EDSS scores and MSSS only in the subset of the population with prior or current immunomodulatory treatment. Nonuse of COCs was a predictor of disease evolution in SPMS, whether treated or not with immunomodulatory drugs. The annualized relapse rate was not influenced by COC use. No differences in EDSS scores and evolution to SPMS depending on COC formulation were detected. Conclusion(s) Our results suggest that COC use is associated with a less severe disease and less severe evolution. Whether different doses or types of progestin may have different effects remains to be defined.",
keywords = "Disability, multiple sclerosis, neurologic outcome, oral contraceptives, sex steroids",
author = "Giulia Gava and Ilaria Bartolomei and Antonietta Costantino and Marta Berra and Stefano Venturoli and Fabrizio Salvi and Meriggiola, {Maria Cristina}",
year = "2014",
doi = "10.1016/j.fertnstert.2014.03.054",
language = "English",
volume = "102",
pages = "116--122",
journal = "Fertility and Sterility",
issn = "0015-0282",
publisher = "Elsevier Inc.",
number = "1",

}

TY - JOUR

T1 - Long-term influence of combined oral contraceptive use on the clinical course of relapsing-remitting multiple sclerosis

AU - Gava, Giulia

AU - Bartolomei, Ilaria

AU - Costantino, Antonietta

AU - Berra, Marta

AU - Venturoli, Stefano

AU - Salvi, Fabrizio

AU - Meriggiola, Maria Cristina

PY - 2014

Y1 - 2014

N2 - Objective To assess the long-term effects of combined oral contraceptives (COCs) on the clinical course of relapsing-remitting multiple sclerosis (RRMS), focusing on disability progression and evolution to secondary-progressive multiple sclerosis (SPMS). Design Retrospective and exploratory study. Setting Academic medical center. Patient(s) A total of 174 women with clinically confirmed MS; of these, 33 had evolved to SPMS at the time of enrollment in the study, whereas 141 still had a relapsing-remitting form of disease. Intervention(s) Women were interviewed to obtain gynecologic and obstetric history. Main Outcome Measure(s) Expanded Disability Status Scale (EDSS); Multiple Sclerosis Severity Score (MSSS); annualized relapse rate; evolution to SPMS. Result(s) Mean ± SD duration of disease was 14.3 ± 9.8 years. Compared with non-users of COCs, COC users had lower EDSS scores and MSSS only in the subset of the population with prior or current immunomodulatory treatment. Nonuse of COCs was a predictor of disease evolution in SPMS, whether treated or not with immunomodulatory drugs. The annualized relapse rate was not influenced by COC use. No differences in EDSS scores and evolution to SPMS depending on COC formulation were detected. Conclusion(s) Our results suggest that COC use is associated with a less severe disease and less severe evolution. Whether different doses or types of progestin may have different effects remains to be defined.

AB - Objective To assess the long-term effects of combined oral contraceptives (COCs) on the clinical course of relapsing-remitting multiple sclerosis (RRMS), focusing on disability progression and evolution to secondary-progressive multiple sclerosis (SPMS). Design Retrospective and exploratory study. Setting Academic medical center. Patient(s) A total of 174 women with clinically confirmed MS; of these, 33 had evolved to SPMS at the time of enrollment in the study, whereas 141 still had a relapsing-remitting form of disease. Intervention(s) Women were interviewed to obtain gynecologic and obstetric history. Main Outcome Measure(s) Expanded Disability Status Scale (EDSS); Multiple Sclerosis Severity Score (MSSS); annualized relapse rate; evolution to SPMS. Result(s) Mean ± SD duration of disease was 14.3 ± 9.8 years. Compared with non-users of COCs, COC users had lower EDSS scores and MSSS only in the subset of the population with prior or current immunomodulatory treatment. Nonuse of COCs was a predictor of disease evolution in SPMS, whether treated or not with immunomodulatory drugs. The annualized relapse rate was not influenced by COC use. No differences in EDSS scores and evolution to SPMS depending on COC formulation were detected. Conclusion(s) Our results suggest that COC use is associated with a less severe disease and less severe evolution. Whether different doses or types of progestin may have different effects remains to be defined.

KW - Disability

KW - multiple sclerosis

KW - neurologic outcome

KW - oral contraceptives

KW - sex steroids

UR - http://www.scopus.com/inward/record.url?scp=84903387553&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84903387553&partnerID=8YFLogxK

U2 - 10.1016/j.fertnstert.2014.03.054

DO - 10.1016/j.fertnstert.2014.03.054

M3 - Article

C2 - 24794311

AN - SCOPUS:84903387553

VL - 102

SP - 116

EP - 122

JO - Fertility and Sterility

JF - Fertility and Sterility

SN - 0015-0282

IS - 1

ER -